UBS reaffirmed its Buy rating and $158 price target for Abbott Laboratories (ABT) following Abbott's agreement to acquire Exact Sciences for $105 per share. This acquisition, expected to close in Q2 2026, will expand Abbott's Diagnostics division and venture into cancer care with Exact Sciences' Cologuard test. UBS projects Abbott will outperform competitors in sales and EPS starting in 2026 due to its medical technology profile and double-digit growth.

<p>UBS has reaffirmed its Buy rating and $158 price target for Abbott Laboratories following its acquisition of Exact Sciences, marking the largest medtech sector acquisition this year. Abbott is considered a top slow growth stock to invest in.</p>

UBS Reaffirms Buy Rating on Abbott Laboratories (ABT) Amid Exact Sciences Acquisition